Background

• Occurring primarily in post-menopausal women, epithelial ovarian carcinoma (EOC) is typically diagnosed at late stages resulting in a high recurrence rate and a low five-year overall survival rate.
• The anti-Mullerian hormone receptor II (AMHR2) is expressed in most EOC.
• AMHR2 is normally expressed in ovarian tissue but turned off in postmenopausal ovaries.

Technology Overview

• Cleveland Clinic has developed a monoclonal antibody against AMHR2.
• Vaccination against AMHR2-ED has demonstrated inhibition of the growth of murine EOCs through CD4+ T- cells that facilitate B-cells to produce AMHR2ED-specific IgG.
• A panel for AMHR2-ED was developed to find an antibody that would mimic the clinical effectiveness of the polyclonal IgG response resulting from AMHR2ED vaccination.
• Treatment